Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213037-26-000011
Filing Date
2026-05-14
Accepted
2026-05-14 16:00:37
Documents
49
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crdf-20260331.htm   iXBRL 10-Q 1598628
2 EX-10.1 crdf-ex10_1.htm EX-10.1 91491
3 EX-10.2 crdf-ex10_2.htm EX-10.2 99630
4 EX-31.1 crdf-ex31_1.htm EX-31.1 14549
5 EX-31.2 crdf-ex31_2.htm EX-31.2 14430
6 EX-32.1 crdf-ex32_1.htm EX-32.1 7646
7 EX-32.2 crdf-ex32_2.htm EX-32.2 7527
  Complete submission text file 0001213037-26-000011.txt   7148898

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20260331.xsd EX-101.SCH 727192
53 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20260331_htm.xml XML 1556880
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35558 | Film No.: 26978509
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)